Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Maria Diaz"'
Autor:
Miran Blanchard, Kevin J. Harrington, Jill Thompson, Shane Zaidi, Richard G. Vile, Michael P. Grams, Rosa Maria Diaz, Kevin G. Shim, Kenneth R. Olivier, Keith M. Furutani, Hardev Pandha, Alan Melcher, Svetomir N. Markovic, Sean S. Park, Karishma Rajani
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 93:577-587
Purpose The oligometastatic state is an intermediate state between a malignancy that can be completely eradicated with conventional modalities and one in which a palliative approach is undertaken. Clinically, high rates of local tumor control are pos
Autor:
Alan Melcher, Richard G. Vile, Jill Thompson, Timothy Kottke, Rosa Maria Diaz, Timothy E. Peterson, Kevin G. Shim, Peter Selby, Karishma Rajani, Ian F. Parney, Elizabeth Ilett, Susan C Short, Shane Zaidi, Julia V. Cockle
Publikováno v:
Neuro-Oncology. 18:518-527
Background Systemic delivery of a complementary cDNA library expressed from the vesicular stomatitis virus (VSV) treats tumors by vaccinating against a wide range of tumor associated antigens (TAAs). For subcutaneous B16 melanomas, therapy was achiev
Autor:
Kevin G. Shim, Timothy Kottke, Nicolas Boisgerault, Kevin J. Harrington, Shane Zaidi, Jill Thompson, Laura Evgin, Peter Selby, Diana Rommelfanger, Hardev Pandha, Richard G. Vile, Rosa Maria Diaz, Elizabeth Ilett, Alan Melcher, Matthew C. Coffey
Understanding how incompletely cleared primary tumors transition from minimal residual disease (MRD) into treatment-resistant, immune-invisible recurrences has major clinical significance. We show here that this transition is mediated through the sub
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de43de651a3b9fba7a3b2ea55d6d0393
https://europepmc.org/articles/PMC5858196/
https://europepmc.org/articles/PMC5858196/
Autor:
Diana Rommelfanger-Konkol, Peter Selby, Timothy Kottke, Elizabeth Ilett, Kevin J. Harrington, Karishma Rajani, Shane Zaidi, Hardev Pandha, Jose S. Pulido, O Donnelly, Alan Melcher, Richard G. Vile, Rosa Maria Diaz, Vanesa Alonso-Camino, Jill Thompson
Publikováno v:
Molecular Therapy. 22(11):1936-1948
Previously, we showed that vesicular stomatitis virus (VSV) engineered to express a cDNA library from human melanoma cells (ASMEL, Altered Self Melanoma Epitope Library) was an effective systemic therapy to treat subcutaneous (s.c.) murine B16 melano
Autor:
Timothy Kottke, Rosa Maria Diaz, Jill Thompson, Diana Rommelfanger, Phonphimon Wongthida, Karen M. Kaluza, Richard G. Vile
Publikováno v:
Cancer Research. 72:4753-4764
Oncolytic virotherapy offers the potential to treat tumors both as a single agent and in combination with traditional modalities such as chemotherapy and radiotherapy. Here we describe an effective, fully systemic treatment regimen, which combines vi
Autor:
Christine M. Pulido, Jill Thompson, Timothy Kottke, Rosa Maria Diaz, Feorillo Galivo, Alan Melcher, Phonphimon Wongthida, Diana Rommelfanger, Richard G. Vile, Karen M. Kaluza
Publikováno v:
Human Gene Therapy. 22:1343-1353
We have shown that the antitumor activity of vesicular stomatitis virus (VSV) against B16ova tumors in C57BL/6 mice is predominantly due to innate antiviral immune effectors. We have also shown that the innate immune-activating properties of VSV can
Autor:
Alan Melcher, Feorillo Galivo, Jill Thompson, Kevin J. Harrington, Steven M. Albelda, Rosa Maria Diaz, Timothy Kottke, Phonphimon Wongthida, Candice Willmon, Richard G. Vile
Publikováno v:
Molecular Therapy. 19(1):140-149
Despite having potent oncolytic activity, in vitro, direct intratumoral injection of oncolytic vesicular stomatitis virus (VSV) into established AE17ova mesothelioma tumors in C57Bl/6 mice had no therapeutic effect. During studies to combine systemic
Autor:
Jill Thompson, Rosa Maria Diaz, Phonphimon Wongthida, Timothy Kottke, Alan Melcher, Feorillo Galivo, Richard G. Vile
Publikováno v:
Molecular Therapy. 19:150-158
We show here, for the first time to our knowledge, that the antitumor therapy of oncolytic vesicular stomatitis virus (VSV) in the B16ova model depends upon signaling through myeloid differentiation primary response gene 88 (MyD88) in host cells. VSV
Autor:
Timothy Kottke, Jill Thompson, Richard G. Vile, Jose S. Pulido, Matthew C. Coffey, John D. Chester, Geoff Hall, Kevin J. Harrington, Peter Selby, Hardev Pandha, Rosa Maria Diaz, Heung Chong, Alan Melcher
Publikováno v:
Journal of Clinical Investigation. 120:1551-1560
Clinical trials of oncolytic virotherapy have shown low toxicity and encouraging signs of efficacy. However, it remains critically important to develop methods for systemic viral delivery if such therapies are to be clinically implemented to treat es
Autor:
Jill Thompson, Uma Thanarajasingam, Rosa Maria Diaz, Alan Melcher, Phonphimon Wongthida, Dragan Jevremovic, Feorillo Galivo, Glen N. Barber, Timothy Kottke, Richard G. Vile
Publikováno v:
Human Gene Therapy. 21:439-450
Oncolytic virotherapy can be achieved in two ways: (1) by exploiting an innate ability of certain viruses to selectively replicate in tumor tissues, and (2) by using viruses to deliver toxic or immunostimulatory genes to tumors. Vesicular stomatitis